| dc.contributor.author |
Mahesh, R. |
|
| dc.date.accessioned |
2023-11-24T04:24:49Z |
|
| dc.date.available |
2023-11-24T04:24:49Z |
|
| dc.date.issued |
2016-01 |
|
| dc.identifier.uri |
https://www.prd-journal.com/article/S1353-8020(15)00877-9/fulltext |
|
| dc.identifier.uri |
http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13249 |
|
| dc.description.abstract |
The prevalence of depression is about 2-3 times higher in diabetic patients compared to the general population, yet this comorbidity is poorly treated. This may partly be contributed to the inefficient pharmacotherapy. We evaluated if a novel 5HT3 receptor antagonist 4i (N-(3-Chloro-2-methylphenyl) quinoxalin-2-carboxamide), can prevent depression-like behavior associated with diabetes in mice. Also, the role of oxidative stress in antidepressant action of 4i was investigated. |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
Elsevier |
en_US |
| dc.subject |
Pharmacy |
en_US |
| dc.subject |
Diabetic mice |
en_US |
| dc.subject |
Antagonists |
en_US |
| dc.subject |
Antidepressant |
en_US |
| dc.title |
4i (N-(3-Chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist alleviates depressive behavior evoked in streptozotocin-induced diabetic mice: Role of oxidative stress |
en_US |
| dc.type |
Article |
en_US |